

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

CRITICAL THERAPEUTICS INC
Form SC 13G/A
June 30, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response.....11

SCHEDULE 13G

Under the Securities and Exchange Act of 1934

(Amendment No. 1)*

CRITICAL THERAPEUTICS INC.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

22674T 10 5

(CUSIP Number)

June 20, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 22674T 10 5

13G

Page 1 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Ventures VI, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 4,058,432

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 4,058,432

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,058,432

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

11.93%

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

12. TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.22674T 10 5

13G

Page 2 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Partners VI, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 5. SOLE VOTING POWER

SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 4,058,432

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 4,058,432

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,058,432

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.93%

12. TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 3 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Ventures VII, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 1,478,103

EACH 7. SOLE DISPOSITIVE POWER
REPORTING

PERSON 8. SHARED DISPOSITIVE POWER
WITH 1,478,103

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,478,103

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.34%

12. TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 4 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

HealthCare Partners VII, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 1,478,103

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 1,478,103

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,478,103

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.34%

12. TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 5 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

James H. Cavanaugh, Ph.D.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 5,536,535

EACH 7. SOLE DISPOSITIVE POWER
REPORTING

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

PERSON 8. SHARED DISPOSITIVE POWER

WITH 5,536,535

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,536,535

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

16.28%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 6 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Harold R. Werner

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER

SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 5,536,535

EACH 7. SOLE DISPOSITIVE POWER

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 5,536,535

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,536,535

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

16.28%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 7 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

William Crouse

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER

SHARES

BENEFICIALLY 6. SHARED VOTING POWER

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

OWNED BY 4,058,432

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 4,058,432

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,058,432

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.93%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 8 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

John W. Littlechild

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 5,536,535

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 5,536,535

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,536,535

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

16.28%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 9 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Christopher Mirabelli, Ph.D.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3. SEC USE ONLY

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 5,536,535

EACH 7. SOLE DISPOSITIVE POWER

REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 5,536,535

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,536,535

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
16.28%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 22674T 10 5

13G

Page 10 of 15 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Augustine Lawlor

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 5,536,535

EACH 7. SOLE DISPOSITIVE POWER
REPORTING

PERSON 8. SHARED DISPOSITIVE POWER
WITH 5,536,535

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,536,535

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
16.28%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

Eric Aguiar, Ph.D.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER
SHARES

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY 5,536,535

EACH 7. SOLE DISPOSITIVE POWER
REPORTING

PERSON 8. SHARED DISPOSITIVE POWER

WITH 5,536,535

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,536,535

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
16.28%

12. TYPE OF REPORTING PERSON*

IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

Item 1(a). Name of Issuer:

Critical Therapeutics, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

60 Westview Street
Lexington, MA 02421

Item 2(a). Name of Person Filing:

HealthCare Ventures VI, L.P. ("HCV VI"), HealthCare Partners VI, L.P. ("HCP VI"), HealthCare Ventures VII, L.P. ("HCV VII"), HealthCare Partners VII, L.P. ("HCP VII"), Drs. Cavanaugh, Mirabelli and Aguiar, and Messrs. Werner, Littlechild, Crouse and Lawlor. See attached Exhibit A, which is a copy of their agreement in writing to file this statement on behalf of each of them(1).

Item 2(b). Address of Principal Business Office, or if None, Residence:

The business address for HCV VI, HCP VI, HCV VII, HCP VII, Dr. Cavanaugh and Messrs. Werner and Crouse is 44 Nassau Street, Princeton, New Jersey 08542. The business address for Drs. Mirabelli and Aguiar and, Messrs. Littlechild and Lawlor is 55 Cambridge Parkway, Suite 301, Cambridge, Massachusetts 02142.

Item 2(c). Citizenship:

HCV VI, HCP VI, HCV VII, and HCP VII are limited partnerships organized under the laws of the State of Delaware. Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Littlechild, Crouse and Lawlor are each United States citizens.

(1) Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Littlechild, and Lawlor are general partners of HCP VI and HCP VII, the general partners of HCV VI and HCV VII, respectively, the record holder of the Issuer's Common Stock reported hereto. In addition, Mr. Crouse is a general partner of HCP VI, the general partner of HCV VI, the record holder of the Issuer's Common Stock reported hereto.

CUSIP No. 22674T 10 5

13G

Page 13 of 15 Pages

Item 2(d). Title of Class of Securities:

Common Stock par value \$0.001 (the "Shares")

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

Item 2(e). CUSIP Number:

22674T 10 5

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not Applicable

- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) Investment company registered under Section 8 of the Investment Company Act.
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

CUSIP No. 22674T 10 5

13G

Page 14 of 15 Pages

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

As of the date of this filing:

HCV VI and HCP VI, owned 4,058,432 Shares of the Issuer's Common Stock.

HCV VII and HCP VII owned 1,478,103 Shares of the Issuer's Common Stock consisting of 1,094,891 Shares of the Issuer's

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

Common Stock and an immediately exercisable Warrant to purchase 383,212 Shares of the Issuer's Common Stock.

Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs Werner, Littlechild and Lawlor each beneficially owned 5,536,535 Shares of the Issuer's Common Stock, consisting of 5,153,323 Shares of the Issuer's Common Stock and an immediately exercisable Warrant to purchase 383,212 Shares of the Issuer's Common Stock.

Mr. Crouse beneficially owned 4,058,432 Shares of the Issuer's Common Stock.

(b) Percent of class:

As of the date of this filing (taking into consideration that approximately 34,000,000 Shares of the Issuer's Common Stock are issued and outstanding):

The 4,058,432 Shares beneficially owned by HCV VI, HCP VI and Mr. Crouse constituted 11.34% of the Shares outstanding.

The 1,478,103 Shares beneficially owned by HCV VII and HCP VII constituted 4.34% of the Shares outstanding.

The 5,536,535 Shares beneficially owned by Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Littlechild and Lawlor constituted 16.28% of the Shares outstanding.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: None

CUSIP No. 22674T 10 5

13G

Page 15 of 15 Pages

(ii) Shared power to vote or to direct the vote:

HCV VI, HCP VI, Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Crouse, Littlechild and Lawlor share the power to vote or direct the vote of those Shares owned by HCV VI.

HCV VII, HCP VII, Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Littlechild and Lawlor share the power to vote or direct the vote of those Shares owned by HCV VII.

(iii) Sole power to dispose or to direct the disposition of: None

(iv) Shared power to dispose or to direct the disposition of:

HCV VI, HCP VI, Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Littlechild, Crouse and Lawlor share the power to dispose of or direct the disposition of those Shares owned by HCV VI.

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

HCV VII, HCP VII, Drs. Cavanaugh, Mirabelli and Aguiar and, Messrs. Werner, Littlechild and Lawlor share the power to dispose of or direct the disposition of those Shares owned by HCV VII.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [].

Not Applicable

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications. By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 22, 2005
Princeton, New Jersey

HealthCare Ventures VI, L.P.
By: its General Partner, HealthCare Partners VI, L.P.

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

June 22, 2005
Princeton, New Jersey
HealthCare Partners VI, L.P.

By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

June 22, 2005
Princeton, New Jersey
HealthCare Ventures VII, L.P.
By: its General Partner, HealthCare Partners VII, L.P.

By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

June 22, 2005
Princeton, New Jersey
HealthCare Partners VII, L.P.

By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

James H. Cavanaugh, Ph.D

June 22, 2005
Princeton, New Jersey

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Harold Werner

June 22, 2005
Princeton, New Jersey

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

William Crouse

June 22, 2005
Princeton, New Jersey

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

John W. Littlechild

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Christopher Mirabelli, Ph.D.

June 22, 2005
Cambridge, Massachusetts

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Augustine Lawlor

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Eric Aguiar, Ph.D.

EXHIBIT A

AGREEMENT

JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree to jointly prepare and file with regulatory authorities a Schedule 13G and any future amendments thereto reporting each of the undersigned's ownership of securities of Critical Therapeutics, Inc. and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned.

June 22, 2005
Princeton, New Jersey

HealthCare Ventures VI, L.P.
By: its General Partner, HealthCare Partners VI, L.P.

By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

June 22, 2005
Princeton, New Jersey

HealthCare Partners VI, L.P.
By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

June 22, 2005
Princeton, New Jersey

HealthCare Ventures VII, L.P.
By: its General Partner, HealthCare Partners VII, L.P.
By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

June 22, 2005
Princeton, New Jersey

HealthCare Partners VII, L.P.
By: /s/ JEFFREY STEINBERG

Jeffrey Steinberg, Administrative Partner

/s/ JEFFREY STEINBERG

Edgar Filing: CRITICAL THERAPEUTICS INC - Form SC 13G/A

June 22, 2005
Princeton, New Jersey

ATTORNEY-IN-FACT

James H. Cavanaugh, Ph.D

June 22, 2005
Princeton, New Jersey

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Harold Werner

June 22, 2005
Princeton, New Jersey

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

William Crouse

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

John W. Littlechild

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Christopher Mirabelli, Ph.D.

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Augustine Lawlor

June 22, 2005
Cambridge, Massachusetts

/s/ JEFFREY STEINBERG
ATTORNEY-IN-FACT

Eric Aguiar, Ph.D.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).